Goldman Sachs Group Inc Ascendis Pharma A/S Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Goldman Sachs Group Inc holds 538,287 shares of ASND stock, worth $111 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
538,287
Previous 585,581
8.08%
Holding current value
$111 Million
Previous $91.3 Million
1.8%
% of portfolio
0.01%
Previous 0.02%
Shares
22 transactions
Others Institutions Holding ASND
# of Institutions
280Shares Held
59.9MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.13 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.13 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.03 Billion15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$917 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$881 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.6B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...